PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20960521-3	2011	In the current study, phase 2 study data of arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in CD33-positive patients with MDS and secondary AML (sAML) were presented.	Arsenic Trioxide	44-60	CD33 molecule	Homo sapiens	101-105	
20960521-3	2011	In the current study, phase 2 study data of arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in CD33-positive patients with MDS and secondary AML (sAML) were presented.	Arsenic Trioxide	62-65	CD33 molecule	Homo sapiens	101-105	
9772451-6	1997	Otherwise, NB4 cells with the treatment of As2O3 at 0.1-0.25 mumol/L for a long time (10 days) have differentiation-related morphology, and their differentiation antigens CD11b and CD33 were also modulated to some extent.	Arsenic Trioxide	43-48	CD33 molecule	Homo sapiens	181-185	
22532027-6	2012	Furthermore, to increase NADPH oxidase activity, ATO could induce cytosolic p67(phox) expression and translocation to membrane.	Arsenic Trioxide	49-52	CD33 molecule	Homo sapiens	76-79	
22532027-7	2012	In addition, knockdown of p67(phox) could abolish ATO-induced ROS production.	Arsenic Trioxide	50-53	CD33 molecule	Homo sapiens	26-29	
22532027-10	2012	In addition, overexpression of c-Src as well as treatment with ATO could stimulate EGFR-Y845/ERK phosphorylation, p21 expression, and cellular arrest/apoptosis, which could be attenuated by pretreatment with apocynin or knockdown of p67(phox).	Arsenic Trioxide	63-66	CD33 molecule	Homo sapiens	233-236